Loading
A phase 2/3 trial of Pertuzumab in HER2-positive breast cancer, run by Shanghai Henlius Biotech, now recruiting.
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer is a phase 2/3 interventional study registered as NCT07294508 by Shanghai Henlius Biotech, with 706 participants planned, started 2026-02-27 and due to reach its primary completion in 2028-01-15. Interventions recorded: HLX87 + HLX22, HLX87 + Pertuzumab, T-Dxd + Pertuzumab and THP.
Shares Pertuzumab, Monoclonal antibodies and the tag pipeline.
Shares Pertuzumab, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Pertuzumab, Monoclonal antibodies and the tag pipeline.
Shares Pertuzumab, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Shares Pertuzumab, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Shares Pertuzumab, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.